Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard, along with clinicians at Washington University in St. Louis have identified biological markers in triple negative breast cancer that are associated with resistance to chemotherapy treatment.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe